

## news release

2003-10-30

## ASTRAZENECA RECEIVES FDA APPROVABLE LETTER FOR SEROQUEL<sup>™</sup> (QUETIAPINE FUMARATE) TABLETS IN TREATMENT OF MANIA

AstraZeneca today announced that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) in response to its Supplemental New Drug Applications (sNDAs) for the use of SEROQUEL as both an adjunct and monotherapy for the treatment of manic episodes associated with bipolar disorder. The company is working closely with the FDA to supply information and to finalize labelling.

## **Media Enquiries:**

Chris Major, +44 (0) 207 304 5028

## **Investor Enquiries:**

Mina Blair-Robinson, +44 (0) 207 304 5084 Jonathan Hunt, +44 (0) 207 304 5087

AstraZeneca AB SE-151 85 Södertälje Sweden 
 Tel
 +46 8 553 260 00

 Fax
 +46 8 553 290 00

 www.astrazeneca.com
 www.astrazeneca.se

Reg Office AstraZeneca AB (publ) SE-151 85 Södertälje Sweden Reg No 556011-7482 VAT No SE556011748201